Preclinical studies have found that overexpression of ITGB3 facilitates cancer invasion and metastasis in HCC 36 and ALK-rearranged NSCLC 37, whereas ITGB3 silencing significantly inhibits EMT and metastasis of triple-negative breast cancer 38. Here, ALK is linked to triple-negative breast carcinoma.